A5046014135- Veterinary Oncology Research
- Parkinson's Disease Mechanisms and Treatments
- Infectious Diseases and Mycology
- Prenatal Screening and Diagnostics
- Neurological disorders and treatments
- Virus-based gene therapy research
- Oral and Maxillofacial Pathology
- Autism Spectrum Disorder Research
- Cancer Diagnosis and Treatment
- Dementia and Cognitive Impairment Research
- Fetal and Pediatric Neurological Disorders
- Neuroscience and Neuropharmacology Research
- Tea Polyphenols and Effects
- Head and Neck Surgical Oncology
- Skin Protection and Aging
- Cancer Research and Treatments
- Sarcoma Diagnosis and Treatment
- Veterinary Medicine and Surgery
- Receptor Mechanisms and Signaling
- Neonatal Respiratory Health Research
- Platelet Disorders and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cystic Fibrosis Research Advances
- Ear and Head Tumors
- Pluripotent Stem Cells Research
Children's Healthcare of Atlanta
2023
Aflac (United States)
2023
Emory University
2023
University of Cambridge
2011-2021
University of Manchester
2015-2020
NIHR Manchester Biomedical Research Centre
2016-2020
University of Liverpool
2005-2019
Manchester Academic Health Science Centre
2015-2018
Salford Royal NHS Foundation Trust
2015-2018
NHS Fife
2018
<h3>Background</h3> Prognosis in Parkinson9s disease (PD) remains poorly understood due to a lack of unbiased data on the natural history treated PD. The CamPaIGN study has been first prospectively track evolution from diagnosis an unselected population-representative incident cohort. We now report 10-year follow-up data, focusing three key irreversible milestones: postural instability (Hoehn and Yahr 3), dementia death. <h3>Methods</h3> cohort was collected between December 2000 2002. Those...
Carriers of mutations in the glucocerebrosidase gene (GBA) are at increased risk developing Parkinson’s disease. The frequency GBA unselected disease populations has not been established. Furthermore, no previous studies have investigated influence on natural history using prospective follow-up. We studied DNA from 262 cases who had recruited diagnosis into one two independent community-based incidence Parkinson's In 121 cases, longitudinal data regarding progression motor disability and...
<h3>Background</h3> Our understanding of the natural history idiopathic Parkinson9s disease (PD) remains limited. In era potential modifying therapies, there is an urgent need for studies assessing evolution treated PD from onset so that relevant outcome measures can be identified clinical trials. No previous have charted progression in unselected patients followed point diagnosis. <h3>Methods</h3> A representative cohort 132 was diagnosis up to 7.9 years (mean 5.2 years). Comprehensive and...
Neurobehavioural and psychiatric symptoms are common in a range of neurodegenerative disorders with distinct profiles which helpful the diagnosis monitoring these disorders. The Cambridge Behavioural Inventory (CBI) has been shown to distinguish frontotemporal dementia (FTD), Alzheimer's disease (AD), Huntington's (HD) Parkinson's (PD), but it is lengthy.To develop shorter version 81 item CBI.CBI data from 450 participants behavioural variant (bv-FTD) (64), AD (96), PD (215) HD (75) were...
Abstract Objective Accurate prenatal diagnosis of genetic conditions can be challenging and usually requires invasive testing. Here, we demonstrate the potential next‐generation sequencing (NGS) for analysis cell‐free DNA in maternal blood to transform monogenic disorders. Methods Analysis using a PCR restriction enzyme digest (PCR–RED) was compared with novel NGS assay pregnancies at risk achondroplasia thanatophoric dysplasia. Results PCR–RED performed 72 cases correct 88.6%, inconclusive...
<b>Objective</b> To investigate the benefits and costs of implementing non-invasive prenatal testing (NIPT) for Down's syndrome into NHS maternity care pathway. <b>Design</b> Prospective cohort study. <b>Setting</b> Eight units across United Kingdom between 1 November 2013 28 February 2015. <b>Participants</b> All pregnant women with a current risk on screening at least 1/1000. <b>Main outcome measures</b> Outcomes were uptake NIPT, number cases detected, invasive...
Abstract Objectives We aim to develop non‐invasive prenatal diagnosis (NIPD) for cystic fibrosis (CF) and determine costs implications implementation. Methods A next‐generation sequencing assay was developed detect ten common CF mutations exclusion of the paternal mutation in maternal plasma. Using uptake data from a study exploring views on NIPD CF, total test‐related were estimated current care pathway compared with those incorporating NIPD. Results The reliably predicted status all...
Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy initiated prior to laboratory confirmation of infection because most deaths from HPS occur within 48 h hospitalization. Thirty patients confirmed HPS, 105 without 5 adequate diagnostic testing were enrolled. This observational study arguably provides complete information...
Non-invasive prenatal testing (NIPT) for aneuploidies is now available through commercial companies in many countries, including private practice the United Kingdom (UK). Thorough evaluation of service delivery requirements are needed to facilitate NIPT being offered more widely within state funded healthcare systems such as UK's National Health Service (NHS). Successful implementation will require development laboratory standards, consideration stakeholder views, an analysis costs and...
Abstract Background Long‐term population‐representative data on motor fluctuations and levodopa‐induced dyskinesias in Parkinson's disease is lacking. Methods The Cambridgeshire Incidence from GP to Neurologist (CamPaIGN) cohort comprises incident PD cases followed for up 13 years (n = 141). Cumulative incidence of risk factors were assessed using Kaplan‐Meyer Cox regression analyses. Results was 54.3% 14.5%, respectively, at 5 100% 55.7%, 10 years. Higher baseline UPDRS‐total SNCA...
Abstract Objective Evaluate the costs of offering non‐invasive prenatal diagnosis (NIPD) for single gene disorders compared to traditional invasive testing inform NIPD implementation into clinical practice. Method Total using or pathways were a representative set disorders. Results For autosomal dominant conditions, where molecular techniques are straightforward, cost £314 less than testing. recessive and X‐linked conditions requires more complicated technical approaches total testing, e.g....
Safe systemic protection from the health hazards of ultraviolet radiation (UVR) in sunlight is desirable. Green tea consumed globally and reported to have anti-inflammatory properties, which may be mediated through impact on cyclooxygenase lipoxygenase pathways. Recent data suggest that green catechins (GTCs) reduce acute UVR effects, but human trials examining their photoprotective potential are scarce. We performed a double-blind, randomized, placebo-controlled trial examine whether GTCs...
Many pet cats and dogs are fed dry extruded kibbled food by measuring cup, yet the precision accuracy of this feeding strategy is not known. Over 12 studies, we assessed weighing out portions, various foods, cup. Poor was noted in all with intra- inter-subject coefficients variation ranging from 2 to 13% 28% respectively. Variable also noted, which ranged an 18% under-estimate 80% over-estimate portion size. No specific factors were associated imprecision, but degree inaccuracy negatively...
To develop a prognostic model to predict disease outcomes in individual patients with Parkinson (PD) and perform an external validation study independent cohort.Model development was done the Comorbidity Aging Rehabilitation Patients: The Influence on Activities (CARPA) cohort (Netherlands). External performed using Cambridgeshire Parkinson's Incidence from GP Neurologist (CamPaIGN) (UK). Both are longitudinal incident studies that prospectively followed up PD time of diagnosis. A composite...
Background: There is currently little evidence regarding the selection of patients for clinical trials in Parkinson's Disease (PD), especially those involving experimental therapies delivered using invasive techniques. Objective: Understanding which